Section Arrow
AAPG.NASDAQ
- Ascentage Pharma Group
Quotes are at least 15-min delayed:2026/06/25 04:18 EDT
Pre Market
Last
 16.34
-0.74 (-4.33%)
Bid
16.3
Ask
20.08
High 16.53 
Low 16.34 
Volume 114 
Regular Hours (Closed)
Last
 17.08
+0.07 (+0.41%)
Day High 
17.08 
Prev. Close
17.01 
1-M High
20.9 
Volume 
7.06K 
Bid
16.3
Ask
20.08
Day Low
17.01 
Open
17.01 
1-M Low
16.92 
Market Cap 
1.59B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 17.16 
20-SMA 18.22 
50-SMA 21.03 
52-W High 48.45 
52-W Low 16.92 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.96/-2.19
Enterprise Value
2.34B
Balance Sheet
Book Value Per Share
2.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
574.12M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0095-0.0322-77.22%-- 
Pre Market -- -- --
CALCCalciMedica0.5973-0.206-25.64%-- 
Pre Market 0.5838 -0.0135 -2.26%
ABSIAbsci Corp10.075+2.665+35.96%-- 
Pre Market 10.0742 -0.0008 -0.01%
EVGNEvogene Ltd.0.4392-0.0518-10.55%-- 
Pre Market 0.4172 -0.022 -5.01%
HUMAHumacyte0.6977-0.0027-0.39%-- 
Pre Market 0.7437 +0.046 +6.59%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.